Romosozumab plus alendronate led to a greater improvement in bone strength than alendronate alone in postmenopausal women ...

Using data from 638,999 patients, a new study by a research team at the Warren Alpert Medical School found that the incidence ...

Exclusion criteria were a T score of −2.5 or less at any of these sites, any major systemic illness or metabolic bone disease, a previous clinical spine or hip fracture, use of any ...

For early postmenopausal women, zoledronate administered at baseline and 5 years is effective for preventing morphometric vertebral fracture.

Intravenous zoledronate (Reclast) administered once every 5 years reduced the incidence of morphometric vertebral fractures in early postmenopausal women, a randomized trial showed. Over 10 years ...